CheckMyRecalls

10,013 recalls · updated 20 Nov 2026

Mylan Institutional, Inc. recalls Levothyroxine Sodium Tablets

Read the official FDA notice

Published
26 Mar 2025
Units affected
2 products
Agency
FDA
Country
United States

The hazard

Super-Potent Drug: Out of specification potency results were obtained.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), Rx Only, 100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each) per carton, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 51079-443-20.

Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), Rx Only, 100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each) per carton, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 51079-445-20.

Brand / company
Mylan Institutional, Inc.
Codes / lots
Lot 3115773, Exp. 03/31/2025 | Lot 3116074, Exp. 09/30/2025
Distribution
Nationwide in the USA
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 26 Mar 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.